Get started
Author

Daniel Korr

Observed names: D. Korr, Korr, Daniel
ORCID: 0000-0002-6250-6344
Observed ORCID: 0000-0002-6250-6344
OpenAlex ID: A5091637701
LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain
2005 · Daniel Korr, Luisella Toschi, et al. · Cellular Signalling · 115
MTG1 Codes for a Conserved Protein Required for Mitochondrial Translation
2003 · Antoni Barrientos, Daniel Korr, et al. · Molecular Biology of the Cell · 70
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2025 · Franziska Siegel, Stephan Siegel, et al. · Cancer Discovery · 34
In vitro characterization of ZK 230211—A type III progesterone receptor antagonist with enhanced antiproliferative properties
2010 · Wiebke Afhüppe, Johanna M. Beekman, et al. · The Journal of Steroid Biochemistry and Molecular Biology · 28
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists
2022 · Douglas L. Orsi, Steven J. Ferrara, et al. · Bioorganic & Medicinal Chemistry · 19
PDF
Concentration Dependence of the Unbound Partition Coefficient Kpuu and Its Application to Correct for Exposure-Related Discrepancies between Biochemical and Cellular Potency of KAT6A Inhibitors
2020 · Cornelius Trünkle, Christian Lechner, et al. · Drug Metabolism and Disposition · 18
PDF
Binding Properties of Agonists and Antagonists to Distinct Allosteric States of the Nicotinic Acetylcholine Receptor Are Incompatible with a Concerted Model
2000 · Michael Krauss, Daniel Korr, et al. · Journal of Biological Chemistry · 18
PDF
BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
2022 · F. Siegel, S. Siegel, et al. · European Journal of Cancer · 17
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor
2024 · Antonius ter Laak, Roman C. Hillig, et al. · Journal of Medicinal Chemistry · 10
PDF
Abstract 4035: Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer
2023 · Franziska Siegel, Gizem Karsli-Uzunbas, et al. · Cancer Research · 9
Abstract 1470: Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions
2021 · Franziska Siegel, Stephan Siegel, et al. · Cancer Research · 7
Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al. · 1
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al. · 1
KAT6A–inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches
2026 · Vera Puetter, Léa Bouché, et al. · Acta Crystallographica Section D Structural Biology
Abstract 7064: Development of a new class of KAT6A/B inhibitors with in vivo efficacy.
2026 · Antonius ter Laak, Roman Hillig, et al. · Cancer Research
Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
PDF
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
PDF
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
PDF
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
PDF
Figure S6 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
PDF
Works count: 32
Citation count: 347
H-index: 9
I10-index: 9
Year
Topic
Type